THE ULTIMATE RESOURCE FOR DEALING WITH CANCER IN PREGNANCY

Cancer diagnosis during pregnancy presents one of the most challenging scenarios in oncology and obstetrics, creating profound ethical, medical, and emotional dilemmas. Balancing the urgent need for effective cancer treatment with the paramount importance of safeguarding fetal development requires meticulous planning and a highly specialized, multidisciplinary approach.

Understanding the Scope and Epidemiology 

Cancer diagnosis coinciding with pregnancy is uncommon, affecting approximately 1 in 1,000 pregnancies. While pregnancy itself doesn’t directly increase cancer risk, the average age of childbearing has risen, overlapping with the age range where cancer incidence begins to climb. The most common malignancies diagnosed during pregnancy are those prevalent in reproductive-age women:

• Breast Cancer: The most frequent pregnancy-associated cancer (1:3000 to 1:10,000 pregnancies), often diagnosed at a later stage due to pregnancy-related physiological breast changes.
• Cervical Cancer: Prevalent due to routine prenatal Pap smears revealing abnormalities (1:10,000 pregnancies).
• Hematologic Malignancies: Including Hodgkin lymphoma, non-Hodgkin lymphoma, and leukemia.
• Melanoma: Aggressiveness can be debated; hormonal influences are complex.
• Thyroid Cancer: Often diagnosed incidentally during neck imaging or palpation.
• Ovarian Cancer: Adnexal masses are common in pregnancy, but few are malignant. The key challenge lies in distinguishing physiological changes from pathological signs, often leading to delayed diagnosis.

Overcoming Diagnostic Challenges 

Diagnosing cancer in pregnancy requires careful consideration to maximize maternal benefit while minimizing fetal risk:

• Clinical Suspicion: Unexplained symptoms like persistent masses, abnormal bleeding, unexplained pain, or neurological changes should never be dismissed as “normal pregnancy complaints.”
• Imaging:
  • Ultrasound: The primary and safest modality for initial evaluation of masses and guiding biopsies.
  • MRI (without Gadolinium): Considered safe at all gestations. Excellent for brain, liver, spinal, and pelvic imaging. Gadolinium contrast is avoided during pregnancy due to fetal risk.
  • Mammography: Can be performed with abdominal shielding; sensitivity is reduced due to increased breast density. Ultrasound is preferred initially.
  • CT Scans: Radiation exposure is a concern. Limited, targeted CT with shielding may be unavoidable in emergencies (e.g., trauma, suspected pulmonary embolism). Chest CT delivers less radiation than abdominal/pelvic CT.
  • PET-CT: Generally contraindicated due to significant radiation from the radiotracer FDG.
• Biopsy: Essential for definitive diagnosis. Procedures like core needle biopsy, skin biopsy, or even lymph node excision under local anesthesia are safe. Cervical conization carries miscarriage risk but may be necessary.
• Tumor Markers: Interpretation is complex. Many markers (CA-125, AFP, hCG, CEA, CA 15-3) are physiologically elevated during pregnancy, reducing their diagnostic specificity. They should not be used for screening but may help monitor known disease.

Treatment Strategies – Balancing Efficacy and Fetal Safety 

Treatment is highly individualized, considering cancer type, stage, gestational age, patient preferences, and fetal risks. The approach evolves with pregnancy trimester.

• General Principles:
  • Multidisciplinary Team (MDT): Crucial involvement of obstetrician/maternal-fetal medicine specialist, medical, radiation, and surgical oncologists, genetic counselor, neonatologist, psychologist, and pharmacist.
  • Timing: Treatment is often deferred until after the first trimester (weeks 1-12) if possible, when organogenesis occurs and fetal vulnerability is highest. Many treatments become feasible in the 2nd and 3rd trimesters with careful planning.
  • Goal: Offer the mother the best possible cancer treatment while protecting the fetus. Terminating a wanted pregnancy is rarely necessary for treatment; alternatives usually exist.
• Treatment Modalities:
  • Surgery: Generally the preferred initial treatment when feasible. Local or regional anesthesia is safest. General anesthesia requires specialized techniques to maintain uteroplacental blood flow. Laparoscopic techniques are increasingly used. Surgery can be performed relatively safely throughout pregnancy after fetal viability considerations, though the first trimester is avoided if possible.
  • Chemotherapy: MAJOR CONSIDERATION: Avoided during the first trimester due to high risk of major congenital malformations (10-20% risk). Safely administered in the 2nd and 3rd trimesters. Most chemotherapeutic agents do not cross the placenta in significant amounts due to molecular size and placental efflux pumps, although exceptions exist (e.g., methotrexate is strictly contraindicated). Regimens are chosen to minimize known teratogens. Common safe(r) agents include anthracyclines (doxorubicin), taxanes (paclitaxel, docetaxel), cyclophosphamide (later trimesters), and platinum agents (cisplatin, carboplatin). Chemotherapy is typically stopped 3-4 weeks before anticipated delivery to allow maternal bone marrow recovery and reduce neonatal complications like cytopenias or infection risk.
  • Radiotherapy: Extremely challenging due to unavoidable scatter radiation to the fetus. Risk depends on dose, field location, gestational age, and fetal proximity. High-risk: Especially first trimester (CNS malformations) and abdominal/pelvic fields at any gestation (fetal damage, growth restriction, childhood cancer risk). Potentially feasible with extreme caution: Radiotherapy to distant sites (e.g., head and neck, breast) during later trimesters with meticulous shielding and planning (e.g., prone positioning). Proton therapy may offer advantages. Breast cancer radiotherapy is almost always postponed until postpartum.
  • Targeted Therapies & Immunotherapy: Data is very limited. Monoclonal antibodies (e.g., trastuzumab for HER2+ breast cancer) can cross the placenta and are associated with oligohydramnios and renal failure in the fetus; generally avoided. Tyrosine kinase inhibitors (TKIs) are often teratogenic. Immunotherapy (e.g., pembrolizumab) may have immune-related adverse effects on the fetus; safety not established. Hormonal therapy (e.g., tamoxifen) is teratogenic/embryotoxic and contraindicated. Novel agents require careful risk-benefit discussions and ideally enrollment in registries (e.g., MotherToBaby).

Assessing Fetal Impact and Obstetric Management

• Fetal Risks:
  • Malformations: Primarily a first-trimester chemotherapy/radiation risk.
  • Growth Restriction & Prematurity: Associated with maternal illness, systemic therapy, abdominal radiation, and iatrogenic delivery. Chemotherapy in the 2nd/3rd trimester increases the risk of fetal growth restriction (FGR) and low birth weight.
  • Hematological Effects: Transient neonatal cytopenias (neutropenia, thrombocytopenia) are common if chemotherapy is administered close to delivery.
  • Long-Term Effects: Long-term data remains relatively sparse. While most children exposed in utero to chemotherapy after the first trimester develop normally, ongoing research addresses potential neurodevelopmental, cardiac, and fertility effects. Radiation exposure carries a lifelong increased risk of childhood cancers.
• Obstetric Management:
  • Enhanced Prenatal Monitoring: Frequent ultrasounds to assess fetal anatomy (detailed scan around 20 weeks), growth, and well-being (Dopplers, NSTs as pregnancy advances). Amniotic fluid volume assessment is crucial.
  • Delivery Timing & Mode: Optimizing delivery timing is critical. The goal is to maximize gestational age while not compromising maternal cancer treatment. Vaginal delivery is generally preferred. Cesarean delivery may be indicated for obstetric reasons or specific maternal conditions (e.g., pelvic tumors obstructing the birth canal, severe thrombocytopenia). Coordination with oncology is essential regarding cessation of chemotherapy.
  • Postpartum Care: Requires seamless transition. Plans for restarting or initiating delayed cancer treatments (chemotherapy, radiotherapy, surgery, targeted therapy) should be finalized pre-delivery. Contraception counseling is vital; pregnancy is usually discouraged during active cancer treatment and for 1-2 years after completion. Lactation: Most chemotherapies contraindicate breastfeeding due to excretion in milk. Hormonal therapies and many other agents also preclude breastfeeding.

Navigating Support, Ethics, and Prognosis

• Psychosocial Support: Diagnosis precipitates intense emotional turmoil – fear, guilt, anxiety, grief. Access to psychological support, counselors, social workers, and peer support groups (e.g., through organizations like Pregnant with Cancer Support Group) is essential for both patient and partner/family.
• Ethical Dilemmas: Balancing maternal autonomy, fetal welfare, and medical recommendations. Scenarios include choices about continuing pregnancy vs. termination, accepting potentially suboptimal maternal treatment to protect the fetus, or opting for aggressive maternal care accepting higher fetal risks. Shared decision-making is paramount, requiring clear communication of risks, benefits, and uncertainties.
• Maternal Prognosis: Survival outcomes for cancer diagnosed during pregnancy, when matched for stage and type, are generally equivalent to non-pregnant women, provided optimal treatment is not unduly delayed. Delays in diagnosis and necessary treatment are the primary factors impacting survival. Breast cancer, the most studied, shows no inherent difference in survival rates.
• Fetal/Neonatal Outcomes: With careful management avoiding teratogens in the first trimester, most infants born to mothers treated for cancer in the 2nd/3rd trimester are healthy at birth. Long-term follow-up studies are ongoing.

Conclusion

Cancer in pregnancy demands a sophisticated, evidence-based, and compassionate approach from a highly coordinated multidisciplinary team. While fraught with complexity, achieving the dual goals of optimizing maternal cancer outcomes while ensuring fetal safety is often possible. Key pillars include accurate diagnosis using safe modalities, strategic timing of treatments (especially avoiding chemotherapy/radiation in the first trimester but utilizing them safely later), meticulous obstetric management, robust psychosocial support, and clear ethical communication. Ongoing research continues to refine safety data for existing therapies and guide the use of novel agents. Through collaborative care and shared decision-making, women diagnosed with cancer during pregnancy can face this challenge with the best possible support and hope for a healthy future for both themselves and their children.

References

1. Amant, F., Berveiller, P., Boere, I. A., Cardonick, E., Fruscio, R., Fumagalli, M., … & Van Calsteren, K. (2022). Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Annals of Oncology, 33(10), 1000-1028.
2. Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., … & Han, S. N. (2015). Pediatric outcome after maternal cancer diagnosed during pregnancy. New England Journal of Medicine, 373(19), 1824-1834.
3. Cardonick, E., Dougherty, R., Grana, G., Gilmandyar, D., Ghaffar, S., & Usmani, A. (2017). Breast cancer during pregnancy: Maternal and fetal outcomes. Cancer Journal, 23(6), 357-362.
4. De Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Gziri, M. M., … & Amant, F. (2018). Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. The Lancet Oncology, 19(3), 337-346.
5. Koren, G., Carey, N., Gagnon, R., Maxwell, C., Nulman, I., & Senikas, V. (2013). Cancer chemotherapy and pregnancy. Journal of Obstetrics and Gynaecology Canada, 35(3), 263-280.
6. Lambertini, M., Peccatori, F. A., & Azim Jr, H. A. (2016). Targeted agents for cancer treatment during pregnancy. Cancer Treatment Reviews, 48, 79-87.
7. Lee, Y. Y., Roberts, C. L., Patterson, J. A., Simpson, J. M., Nicholl, M. C., & Morris, J. M. (2012). A meta-analysis of pregnancy outcomes in women with systemic lupus erythematosus and lupus nephritis. Clinical Journal of the American Society of Nephrology, 7(12), 2061-2071. (While focused on SLE, methodology for meta-analysis is applicable to similar reviews in cancer).
8. Litton, J. K., Theriault, R. L., & Hortobagyi, G. N. (2017). Medical treatment of breast cancer during pregnancy. The Breast, 34, 167-173.
9. Morice, P., Uzan, C., Gouy, S., Verschraegen, C., & Haie-Meder, C. (2012). Gynaecological cancers in pregnancy. The Lancet, 379(9815), 558-569.
10. National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis. ([Specific guidelines vary by cancer; access requires membership/subscription]).
11. Pinnix, C. C., & Milgrom, S. A. (2016). Radiation therapy during pregnancy. Hematology/Oncology Clinics of North America, 30(4), 913-927.
12. van Gerwen, M., Ottevanger, N., Frijstein, M., Gilet, S., Van der Velden, D. L., Verheijen, R. H., … & Amant, F. (2023). Long‐term neurodevelopmental outcome after prenatal exposure to maternal cancer and treatment: a systematic review. Cancer, 129(18), 2799-2812.
13. Wo, J. Y., & Viswanathan, A. N. (2009). Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. International Journal of Radiation Oncology, Biology, Physics, 73(5), 1304-1312.